Investigating immune semaphorins in liver disease and sepsis outcomes
The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis
This study is trying to see how certain immune signals affect the outcomes of sepsis in people with fatty liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital for Infectious Diseases, Croatia Academic / other |
| Locations | 1 site (Zagreb) |
| Trial ID | NCT06021743 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between immune semaphorins and sepsis outcomes in patients with steatotic liver disease (SLD). It will assess the degree of liver steatosis, screen for metabolic syndrome components, and measure serum semaphorin concentrations and inflammatory cytokines. The study seeks to fill the knowledge gap regarding how SLD affects the immune response during sepsis and the potential regulatory role of semaphorins in this context.
Who should consider this trial
Good fit: Ideal candidates include patients with clinical suspicion of sepsis who meet at least two SIRS criteria and have a diagnosis of steatotic liver disease.
Not a fit: Patients with chronic liver disease, immunosuppression, malignancies, or those who consume alcohol above 20 g/day may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of sepsis in patients with steatotic liver disease.
How similar studies have performed: While the role of semaphorins in sepsis is largely unexplored, similar studies have shown promise in understanding immune responses in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 2 or more SIRS (Systemic Inflammatory Response Syndrome) criteria (1. Hyperthermia \>38.3°C or Hypothermia \<36°C; 2. Tachycardia \>90 bpm; 3. Tachypnea \>20 bpm; 3. Leukocytosis (\>12,000 μL-1) or Leukopenia (\<4,000 μL-1)) * clinical suspicion of sepsis * enrolled within 24 hours of hospital admission Exclusion Criteria: * no consent * immunosuppression * malignancies * immune diseases * pregnancy * HIV infection * presence of chronic liver disease * consumption of alcohol \> 20 g/day
Where this trial is running
Zagreb
- University Hospital for Infectious Diseases Zagreb — Zagreb, Croatia (Recruiting)
Study contacts
- Principal investigator: Neven Papic, MD, PhD — School of Medicine, University of Zagreb
- Study coordinator: Nina Vrsaljko, MD
- Email: nvrsaljko@bfm.hr
- Phone: +385914012018
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.